X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
LY3502970 (orforglipron) is a once-daily oral nonpeptide GLP-1 receptor agonist. It is being evaluated in phase 3 clinical trials for the treatment of adults with Type 2 Diabetes.
Lead Product(s): Orforglipron Calcium Hydrate
Therapeutic Area: Endocrinology Product Name: LY3502970
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2023
Details:
LY3502970 (orforglipron), is first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweight.
Lead Product(s): Orforglipron Calcium Hydrate
Therapeutic Area: Nutrition and Weight Loss Product Name: LY3502970
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2023
Details:
LY3502970 (orforglipron), is first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweight.
Lead Product(s): Orforglipron Calcium Hydrate
Therapeutic Area: Nutrition and Weight Loss Product Name: LY3502970
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
